Envestnet Asset Management Inc. Boosts Stock Position in Boston Scientific Corporation $BSX

Envestnet Asset Management Inc. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,804,912 shares of the medical equipment provider’s stock after acquiring an additional 13,947 shares during the period. Envestnet Asset Management Inc.’s holdings in Boston Scientific were worth $301,276,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $37,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BSX has been the subject of several recent analyst reports. Truist Financial raised their price target on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a report on Thursday. Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a report on Friday, October 17th. Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Finally, Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Performance

NYSE BSX opened at $101.08 on Monday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a market capitalization of $149.78 billion, a P/E ratio of 54.06, a PEG ratio of 2.04 and a beta of 0.61. The business has a 50 day moving average price of $101.14 and a 200 day moving average price of $102.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the business posted $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 170,214 shares of company stock worth $17,548,337. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.